Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Monogenetic Disease Therapy Market Revenue Growth On Track For A 10% CAGR Through 2030
The monogenetic disease therapy market has shown robust growth in recent years. It is projected to expand from $28.3 billion in 2025 to $31.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. This historical growth can be attributed to several factors including progress in human genome research, the commencement of early gene therapy trials, an increase in the diagnosis of rare diseases, incentives for orphan drugs, and developments in viral vectors.
The monogenetic disease therapy market is anticipated to experience considerable expansion in the forthcoming years. By 2030, this market is projected to reach $45.58 billion, demonstrating a compound annual growth rate (CAGR) of 10.0%. Factors contributing to this growth during the forecast period include advancements in gene editing platforms, an enlargement of rare disease pipelines, elevated rates of genetic screening, increased financial backing for personalized therapies, and more extensive regulatory endorsements. Key trends identified for this timeframe encompass single gene targeted therapies, programs focused on gene replacement treatment, RNA-based genetic interventions, corrective gene therapies for rare diseases, and the development of precision genetic drugs.
Get A Free Sample Report With In-Depth Market Insights:
Monogenetic Disease Therapy Market Development Factors: What’s Supporting Demand?
The monogenetic disease therapy market is anticipated to expand due to the increasing adoption of precision and personalized medicine. This medical approach customizes disease prevention, diagnosis, and treatment based on an individual’s distinct genetic, molecular, or lifestyle characteristics, aiming to maximize therapeutic efficacy and minimize adverse effects. The growing prevalence of precision and personalized medicine is driven by healthcare providers and patients seeking customized treatments that optimize therapeutic outcomes, reduce negative reactions, and account for individual genetic, molecular, or lifestyle attributes. Monogenetic disease therapy complements precision and personalized medicine by specifically targeting a patient’s genetic mutation, thereby facilitating highly tailored and effective treatments. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, marking an increase from six in 2022. Consequently, the increasing embrace of precision and personalized medicine is a primary catalyst for the expansion of the monogenetic disease therapy market.
Monogenetic Disease Therapy Market Segment Analysis: What Are The Core Market Categories?
The monogenetic disease therapy market covered in this report is segmented –
1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types
2) By Inheritance Pattern: Autosomal; Chromosomal
3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users
Subsegments:
1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies
2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions
3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions
4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy
5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies
Monogenetic Disease Therapy Market Transformation Trends: What Innovations Are Driving Change?
Leading companies within the monogenetic disease therapy market are concentrating on creating novel gene therapies, including protocols specifically aimed at Duchenne muscular dystrophy (DMD), to decelerate the disease’s progression and enhance long-term results for patients. These Duchenne muscular dystrophy–targeted protocols represent organized clinical or therapeutic frameworks, crafted to diagnose, oversee, and treat individuals afflicted with Duchenne muscular dystrophy, with a primary emphasis on impeding disease advancement, boosting muscle functionality, and managing related complications. A notable example is Sarepta Therapeutics Inc., a US-based biopharmaceutical firm, which introduced Elevidys in January 2026 for ambulatory DMD patients who are four years of age or older. The company reported a reduction of up to 73% in the rate of functional decline over three years when contrasted with an external control group, underscoring the critical role of early intervention in modifying the disease’s trajectory and enhancing quality of life.
Monogenetic Disease Therapy Market Key Participants And Competitive Landscape
Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.
View The Full Monogenetic Disease Therapy Market Report:
Monogenetic Disease Therapy Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
